Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Over-the-Counter Pain Reliever, Cobroxin, Now Available in CVS
March 30, 2010

Cobroxin, an over-the-counter (OTC) pain reliever indicated to treat moderate to severe (Stage 2) chronic pain, is now available for purchase in CVS drugstores nationwide.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, is now available for purchase in CVS. With over 7,000 store locations across the United States, CVS is considered the nation’s largest pharmacy chain by store count and by retail pharmacy sales per square foot.

“We are excited to announce the availability of Cobroxin in CVS, as this represents the first major drug store chain to carry Cobroxin nationwide,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As an over-the-counter, non-narcotic, and non-addictive analgesic, we believe that Cobroxin will become the treatment of choice among those suffering from moderate to severe chronic pain,” he added.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

  • All Natural
  • Non-Addictive
  • Non-Narcotic
  • Non-Opiate
  • Long Lasting

In 2009, Nutra Pharma granted an exclusive license to XenaCare Holdings to market and distribute Cobroxin in the United States. Recently, XenaCare Holdings announced that Cobroxin will be available for purchase in Walgreens by May 1, 2010.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the availability of Cobroxin at CVS should not be construed as an indication in any way whatsoever of the value of the Company or its common stock.  The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy


June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics